Key Takeaways:<\/p>\n
<\/p>\n
Oral anticoagulation (OAC) is standard after AF ablation in patients at moderate-to-high risk of stroke, but it carries significant bleeding risks. Left atrial appendage closure (LAAC) offers a mechanical alternative to long-term anticoagulation. The OPTION trial aimed to assess whether LAAC could safely reduce bleeding while maintaining efficacy for stroke prevention (OPTION ClinicalTrials.gov number,\u00a0NCT03795298)<\/a>. The main results were presented at AHA Scientific Sessions 2024 with simultaneous publication<\/a> in the New England Journal of Medicine.<\/em><\/p>\n The OPTION trial was an international, multicenter, randomized study that included 1,600 patients with AF who had a CHA\u2082DS\u2082-VASc score of \u22652 for men or \u22653 for women and who underwent catheter ablation.\u00a0 Patients underwent AF ablation and were randomized 1:1 to receive LAAC or OAC. The primary safety endpoint was non-procedure-related major or clinically relevant nonmajor bleeding at 36 months. The primary efficacy endpoint was a composite of all-cause death, stroke, or systemic embolism, tested for noninferiority. The secondary endpoint assessed major bleeding, including procedure-related events.<\/p>\n A total of 803 patients were assigned to undergo left atrial appendage closure, and 797 to receive anticoagulant therapy. The mean (\u00b1SD) age of the patients was 69.6\u00b17.7 years, 34.1% of the patients were women, and the mean CHA2<\/sub>DS2<\/sub>-VASc score was 3.5\u00b11.3.<\/p>\n In the LAAC group, 8.5% of patients experienced non-procedure-related bleeding events compared to 18.1% in the OAC group (HR, 0.44; 95% CI, 0.33\u20130.59;\u00a0P<0.001\u00a0for superiority) at 36 months. The primary composite efficacy endpoint occurred in 5.3% of the LAAC group versus 5.8% in the OAC group (HR, 0.91; 95% CI, 0.59\u20131.39;\u00a0P<0.001\u00a0for noninferiority). Major bleeding events were reported in 3.9% of patients receiving LAAC compared to 5.0% receiving OAC (HR, 0.77; 95% CI, 0.48\u20131.24;\u00a0P<0.001\u00a0for noninferiority). Complications from LAAC devices or procedures occurred in 2.9% of patients in the LAAC group.<\/p>\n Dr. Oussama Wazni, the lead investigator, highlighted the significance of these findings: \u201cLeft atrial appendage closure represents a viable and potentially safer alternative to oral anticoagulation for stroke prevention in patients after AF ablation.\u201d The OPTION trial demonstrates that LAAC reduces bleeding risks without compromising efficacy, providing a promising treatment pathway for patients at risk of complications from long-term OAC. Further research is warranted to confirm these findings in broader patient populations.<\/p>\n","protected":false},"excerpt":{"rendered":" Key Takeaways: The OPTION TRIAL assessed the safety and efficacy of WATCHMAN FLX in a post-ablation contemporary clinical AF patient population at risk of stroke. The trial showed that left atrial appendage closure after AF ablation was associated with a lower risk of non\u2013procedure-related major or clinically relevant nonmajor bleeding compared with oral anticoagulation.<\/p>\n","protected":false},"author":40616,"featured_media":138588,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[896,8],"tags":[897,45,47,185],"ppma_author":[1070],"class_list":{"0":"post-138587","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-aha-2024","8":"category-news","9":"tag-aha-2024","10":"tag-conference","11":"tag-featured","12":"tag-news","13":"author-joseph-kim-md"},"authors":[{"term_id":1070,"user_id":40616,"is_guest":0,"slug":"joseph-kim-md","display_name":"Joseph Kim MD","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/bf0879bf0ca450025acf71d7345cf24be4748f67f7b0c6423d186a5765c5cda9?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/users\/40616"}],"replies":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=138587"}],"version-history":[{"count":2,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138587\/revisions"}],"predecessor-version":[{"id":138590,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138587\/revisions\/138590"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/media\/138588"}],"wp:attachment":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=138587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=138587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=138587"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fppma_author&post=138587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}